Maintenance Therapy for RAS Wild-Type Metastatic Colorectal Cancer

This phase 2 clinical trial evaluates the biological activity and safety of capecitabine plus cetuximab as a novel maintenance therapy for RAS wild-type metastatic colorectal cancer.

Read the full article here

Related Articles